Gamma-hydroxybutyrate abuse: pharmacology and poisoning and withdrawal management - Marinelli E, Beck R, Malvasi A, Faro AFL, Zaami S.
Gamma-hydroxybutyrate (GHB) is a central nervous system depressant primarily used as a recreational drug of abuse, but also for the treatment of narcolepsy with cataplexy in adult patients and as an adjuvant for control of alcohol withdrawal syndrome. The ... (Source: SafetyLit)
Source: SafetyLit - July 4, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
What Are the Signs of Narcolepsy
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 19, 2020 Category: General Medicine Source Type: news
A cautionary tale about narcolepsy and deferrals to the civilian network - Kinkennon S.
The transformation of Army medicine has been a topic of great concern for all military physicians, regardless of specialty. It has been proposed that 18,000 uniformed military medical personnel be cut (approximately 22% of 2019 uniformed personnel). Pe... (Source: SafetyLit)
Source: SafetyLit - March 11, 2020 Category: International Medicine & Public Health Tags: Commentary Source Type: news
Narcoleptic 15-year-old suffers sudden muscle paralysis if she giggles
Jordan Coomer, from Indiana, suffers from cataplexy, which causes sudden muscle paralysis if she giggles or feels strong emotion. It's a complication of narcolepsy, which can be caused by an infection. (Source: the Mail online | Health)
Source: the Mail online | Health - January 27, 2020 Category: Consumer Health News Source Type: news
Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
DUBLIN, Jan. 22, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on January 21, 2020 seeking... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - January 22, 2020 Category: Drugs & Pharmacology Source Type: news
Jazz Pharmaceuticals sleep disorder drug approved by European Commission
The European Commission has approved Sunosi, a Jazz Pharmaceuticals sleep disorder treatment.
Sunosi was approved, in 75- and 150-milligram doses, to improve wakefulness and reduce excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea who did not respond to primary sleep apnea therapies such as continuous positive airway pressure.
Jazz Pharmaceuticals, which is based in Dublin, Ireland, has major operations in Philadelphia where the company has nearly 200 employees.… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 21, 2020 Category: Biotechnology Authors: John George Source Type: news
Risk of burn injury in patients with narcolepsy: a nationwide population-based cohort study - Chang ET, Lin CL, Chen SF, Shen YC.
Narcolepsy is a rare brain disorder characterized by excessive daytime sleepiness (EDS), cataplexy, hypnagogic hallucinations, and sleep paralysis. Stimulants have been used to relieve the symptoms of EDS. Narcolepsy symptoms may pose a risk to burn injury... (Source: SafetyLit)
Source: SafetyLit - January 16, 2020 Category: International Medicine & Public Health Tags: Burns, Electricity, Explosions, Fire, Scalds Source Type: news
EMA Panel Backs Solriamfetol (Sunosi) for Narcolepsy, OSA EMA Panel Backs Solriamfetol (Sunosi) for Narcolepsy, OSA
The dual-acting dopamine and norepinephrine reuptake inhibitor showed durable effects in reducing excessive sleepiness in patients with narcolepsy or obstructive sleep apnea (OSA).International Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 15, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
Solriamfetol is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea
If approved by the European Commission for... Biopharmaceuticals, Regulatory Jazz Pharmaceuticals, solriamfetol, narcolepsy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 15, 2019 Category: Pharmaceuticals Source Type: news
Novel, Low-Sodium Drug Promising for Narcolepsy Novel, Low-Sodium Drug Promising for Narcolepsy
A novel drug with a low-sodium formulation is both safe and effective for treating symptoms of narcolepsy in adult patients, results from a phase 3 trial suggest.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 3, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
A case of a sleepy taxi driver presenting with narcolepsy - Miskoff JA, Chaudhri M.
Narcolepsy is a sleep disorder, which can manifest in childhood, or adolescence by causing excessive daytime sleepiness, hallucinations, sleep attacks or cataplexy. Although presentation can vary, nearly all patients present with excessive daytime sleepine... (Source: SafetyLit)
Source: SafetyLit - August 21, 2019 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news
FDA Approves Wakix (pitolisant), a First-in-Class Medication for the Treatment of Excessive Daytime Sleepiness in Adult Patients with Narcolepsy
PLYMOUTH MEETING, PA, August 15, 2019— Harmony Biosciences, LLC (Harmony) announced today that the U.S. Food and Drug Administration (FDA) approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness (EDS) in adult patients... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 15, 2019 Category: Drugs & Pharmacology Source Type: news
FDA Okays Pitolisant (Wakix) for Narcolepsy FDA Okays Pitolisant (Wakix) for Narcolepsy
The FDA has approved pitolisant, a first-in-class, nonscheduled treatment option with a novel mechanism of action for adults with narcolepsy.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 15, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
Harmony Biosciences Announces FDA Approval Of WAKIX(R) (Pitolisant), A First-In-Class Medication For The Treatment Of Excessive Daytime Sleepiness In Adult Patients With Narcolepsy
WAKIX represents the first and only non-scheduled treatment approved for patients with narcolepsy in the U.S.
PLYMOUTH MEETING, Pa., Aug. 15, 2019 -- (Healthcare Sales & Marketing Network) -- Harmony Biosciences, LLC (Harmony) announced today that the ... Biopharmaceuticals, FDA Harmony Biosciences, WAKIX, pitolisant, excessive daytime sleepiness, narcolepsy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 15, 2019 Category: Pharmaceuticals Source Type: news
Biomarkers for REM sleep behavior disorder in idiopathic and narcoleptic patients - Antelmi E, Pizza F, Donadio V, Filardi M, Sosero YL, Incensi A, Vandi S, Moresco M, Ferri R, Marelli S, Ferini-Strambi L, Liguori R, Plazzi G.
To search for discriminating biomarkers, 30 patients with idiopathic rapid-eye-movements sleep behavior disorder (iRBD) were compared with 17 patients with RBD within narcolepsy type 1. Both groups underwent extensive examinations, including skin biopsy se... (Source: SafetyLit)
Source: SafetyLit - August 8, 2019 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news
